To provide long-term capital growth through investment mainly in ordinary shares in the US and Canada.
Name | % Net Assets |
---|---|
Exxon Mobil | 5.6% |
Microsoft | 3.5% |
Johnson & Johnson | 3.2% |
Pfizer | 2.5% |
Intel | 2.3% |
General Electric | 2.3% |
ConocoPhillips | 2.1% |
Monsanto | 2.0% |
Lilly (Eli) | 2.0% |
Medtronic | 1.9% |
Key | % Net Assets |
---|---|
Exxon Mobil | 5.6% |
Microsoft | 3.5% |
Johnson & Johnson | 3.2% |
Pfizer | 2.5% |
Other | 85.2% |
Date | 21-Nov-2024 |
---|---|
NAV | 1,510.00p |
Currency | GBP |
Change | 7.00p |
% | 0.47% |
YTD change | 329.00p |
YTD % | 27.86% |
Fund Inception | 15/10/1984 |
---|---|
Fund Manager | Erik Rubingh |
TER | 0.79 (30-Apr-2011) |
Minimum Investment | |
---|---|
Initial | £500000 |
Additional | £25,000 |
Savings | n/a |
Charges | |
---|---|
Initial | 1.00% |
Annual Mang't | 0.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | -0.03 |
You are here: research